{"id":"NCT04591626","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes","officialTitle":"A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-07","primaryCompletion":"2022-04-28","completion":"2022-04-28","firstPosted":"2020-10-19","resultsPosted":"2023-05-24","lastUpdate":"2023-05-24"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dulaglutide","otherNames":["LY2189265"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"1.5 Milligrams (mg) Dulaglutide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, Week 28","effectByArm":[{"arm":"1.5 mg Dulaglutide","deltaMin":-2.03,"sd":0.076},{"arm":"Placebo","deltaMin":-1.08,"sd":0.073}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":12},"locations":{"siteCount":27,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":144},"commonTop":["Diabetic nephropathy","Decreased appetite","Diarrhoea","Nausea","Upper respiratory tract infection"]}}